“As the pace of healthcare innovation accelerates, pharmaceutical companies need partners who can help them scale rapidly with a focus on quality and safety. Jabil and Pii’s combined capabilities can provide end-to-end support for pharmaceutical customers, offering one safe, trusted pair of hands to simplify their entire supply chain,” said Mike Mahaz, senior vice president, Global Business Units, Healthcare, at Jabil.

According to Jabil, this acquisition will significantly enhance the company’s existing parenteral drug delivery offering, which includes the development and production of auto-injectors, pen injectors, inhalers, and on-body pumps. With the addition of Pii’s capabilities across aseptic filling, lyophilization, and oral solid dose manufacturing, Jabil said that it can meet the clinical and commercial drug manufacturing demands of healthcare customers.

“With our shared commitment to creating the best solutions possible for patients around the world, we believe the addition of Pii’s capabilities, supported by over 300 team members, is a perfect fit for Jabil and our customers,” said James O’Gorman, vice president, Pharmaceutical Solutions, at Jabil. “The convergence of Jabil’s and Pii’s complementary capabilities will bolster Jabil's customer offering and support business growth potential as we enter the CDMO market.”

Founded in 1994, Pii today operates four sites on a single US campus in Hunt Valley, Maryland, with a total footprint of over 360,000 square feet.

“We look forward to leveraging Jabil’s extensive expertise to accelerate our mission of delivering best-in-class drug development and manufacturing solutions to our customers and ultimately the patients we serve,” said John Fowler, CEO at Pii.